Antibody World Summit 2004-SRI Conference 19-21 July 2004, Philadelphia, PA, USA.
Identifieur interne : 002B27 ( PubMed/Corpus ); précédent : 002B26; suivant : 002B28Antibody World Summit 2004-SRI Conference 19-21 July 2004, Philadelphia, PA, USA.
Auteurs : Steffen NockSource :
- IDrugs : the investigational drugs journal [ 1369-7056 ] ; 2004.
English descriptors
- KwdEn :
- MESH :
- chemical : Antibodies, Monoclonal, Drugs, Investigational.
- immunology : HIV-1, SARS Virus.
- trends : Research.
- Animals, Drug Design, Drug Industry, Humans, Internationality, Philadelphia, Technology, Pharmaceutical.
Abstract
Overall, the sessions were well attended and a lot of questions were asked. Two-thirds of the speakers were from industry and the rest from academia. Of particular note, The academics presented cutting-edge science in the antibody discovery and development area. Business representatives from various therapeutic antibody companies discussed in detail various aspects and challenges of building a viable therapeutic antibody company.
PubMed: 15470596
Links to Exploration step
pubmed:15470596Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibody World Summit 2004-SRI Conference 19-21 July 2004, Philadelphia, PA, USA.</title><author><name sortKey="Nock, Steffen" sort="Nock, Steffen" uniqKey="Nock S" first="Steffen" last="Nock">Steffen Nock</name><affiliation><nlm:affiliation>Absalus Inc, 2464 Wyandotte Street, Mountain View, CA 94043, USA. snock@abslus.com</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15470596</idno><idno type="pmid">15470596</idno><idno type="wicri:Area/PubMed/Corpus">002B27</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antibody World Summit 2004-SRI Conference 19-21 July 2004, Philadelphia, PA, USA.</title><author><name sortKey="Nock, Steffen" sort="Nock, Steffen" uniqKey="Nock S" first="Steffen" last="Nock">Steffen Nock</name><affiliation><nlm:affiliation>Absalus Inc, 2464 Wyandotte Street, Mountain View, CA 94043, USA. snock@abslus.com</nlm:affiliation></affiliation></author></analytic><series><title level="j">IDrugs : the investigational drugs journal</title><idno type="ISSN">1369-7056</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal</term><term>Drug Design</term><term>Drug Industry</term><term>Drugs, Investigational</term><term>HIV-1 (immunology)</term><term>Humans</term><term>Internationality</term><term>Philadelphia</term><term>Research (trends)</term><term>SARS Virus (immunology)</term><term>Technology, Pharmaceutical</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Drugs, Investigational</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV-1</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Research</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Design</term><term>Drug Industry</term><term>Humans</term><term>Internationality</term><term>Philadelphia</term><term>Technology, Pharmaceutical</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Overall, the sessions were well attended and a lot of questions were asked. Two-thirds of the speakers were from industry and the rest from academia. Of particular note, The academics presented cutting-edge science in the antibody discovery and development area. Business representatives from various therapeutic antibody companies discussed in detail various aspects and challenges of building a viable therapeutic antibody company.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15470596</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1369-7056</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>IDrugs : the investigational drugs journal</Title><ISOAbbreviation>IDrugs</ISOAbbreviation></Journal><ArticleTitle>Antibody World Summit 2004-SRI Conference 19-21 July 2004, Philadelphia, PA, USA.</ArticleTitle><Pagination><MedlinePgn>825-8</MedlinePgn></Pagination><Abstract><AbstractText>Overall, the sessions were well attended and a lot of questions were asked. Two-thirds of the speakers were from industry and the rest from academia. Of particular note, The academics presented cutting-edge science in the antibody discovery and development area. Business representatives from various therapeutic antibody companies discussed in detail various aspects and challenges of building a viable therapeutic antibody company.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nock</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Absalus Inc, 2464 Wyandotte Street, Mountain View, CA 94043, USA. snock@abslus.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>IDrugs</MedlineTA><NlmUniqueID>100883655</NlmUniqueID><ISSNLinking>1369-7056</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015143" MajorTopicYN="N">Philadelphia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15470596</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002B27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15470596
|texte= Antibody World Summit 2004-SRI Conference 19-21 July 2004, Philadelphia, PA, USA.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15470596" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |